Field trial in Vanuatu to assess the effectivess of treating-all pregnant women with hepatitis B with tenofovir prophylaxis to prevent mother-to-child transmission compared to guideline-based care

开始日期2024-03-01

申办/合作机构

The Macfarlane Burnet Institute For Medical Research & Public

CTRI/2023/07/055027 / Not yet recruitingN/A

Utility, Feasibility & Acceptability of a Point of Care Urine Tenofovir Assay to Monitor Treatment & Enhance Adherence to Anti-retroviral Therapy in People Living with HIV

开始日期2023-08-01

申办/合作机构-

NCT05721300 / RecruitingN/AIIT

Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer

The goal of this clinical trial is to test the outcomes of HBsAg(+) patients in the treatments of NAs vs NAs plus IFN . The main questions it aims to answer are:
Clinical effect analysis of nucleoside analogs (NAs) group a group and NAs plus interferon group after 48 weeks of treatment;
Repetitive effect and time effect of different drug treatment at different follow-up time points;
To evaluate the difference of therapeutic effect of NAs or NAs combined with interferon;
Follow up and compare the incidence of early liver cancer in each group. Participants will be asked to receive NAs or NAs combined with interferon treatments, and Regular blood sampling and color ultrasound examination.
Researchers will compare control group to see if occurrence of liver cancer.

开始日期2023-02-10

申办/合作机构

复旦大学附属中山医院

100 项与替诺福韦相关的临床结果

登录后查看更多信息

100 项与替诺福韦相关的转化医学

登录后查看更多信息

100 项与替诺福韦相关的专利（医药）

登录后查看更多信息

5,987

项与替诺福韦相关的文献（医药）

2024-04-12·The Journal of infectious diseases

Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01)

Article

作者: Bumpus, Namandje N ; Weld, Ethel D ; Manohar, Madhuri ; Seigel, Aaron ; Parsons, Teresa ; Bakshi, Rahul P ; Carballo-Dieguez, Alex ; Bagia, Christina ; Marzinke, Mark A ; Anton, Peter ; Engstrom, Jared ; Spiegel, Hans M L ; Edick, Stacey ; Fuchs, Edward J ; Al-Khouja, Amer ; Hendrix, Craig W ; Giguere, Rebecca ; Rohan, Lisa C ; Brand, Rhonda ; Ho, Ken ; Wang, Lin ; Jacobson, Cindy ; Elliott, Julie ; McGowan, Ian ; Hartman, Douglas J

Abstract:

Background:

Despite highly effective HIV preexposure prophylaxis (PrEP) options, no options provide on-demand, nonsystemic, behaviorally congruent PrEP that many desire. A tenofovir-medicated rectal douche before receptive anal intercourse may provide this option.

Methods:

Three tenofovir rectal douches—220 mg iso-osmolar product A, 660 mg iso-osmolar product B, and 660 mg hypo-osmolar product C—were studied in 21 HIV-negative men who have sex with men. We sampled blood and colorectal tissue to assess safety, acceptability, pharmacokinetics, and pharmacodynamics.

Results:

The douches had high acceptability without toxicity. Median plasma tenofovir peak concentrations for all products were several-fold below trough concentrations associated with oral tenofovir disoproxil fumarate (TDF). Median colon tissue mucosal mononuclear cell (MMC) tenofovir-diphosphate concentrations exceeded target concentrations from 1 hour through 3 to 7 days after dosing. For 6–7 days after a single product C dose, MMC tenofovir-diphosphate exceeded concentrations expected with steady-state oral TDF 300 mg on-demand 2-1-1 dosing. Compared to predrug baseline, HIV replication after ex vivo colon tissue HIV challenge demonstrated a concentration-response relationship with 1.9 log10 maximal effect.

Conclusions:

All 3 tenofovir douches achieved tissue tenofovir-diphosphate concentrations and colorectal antiviral effect exceeding oral TDF and with lower systemic tenofovir. Tenofovir douches may provide a single-dose, on-demand, behaviorally congruent PrEP option, and warrant continued development.Clinical Trials Registration . NCT02750540.

2024-04-06·Transactions of the Royal Society of Tropical Medicine and Hygiene

Impact of lamivudine treatment in late pregnancy on the development of the foetal immune response to hepatitis B virus: a meta-analysis in R with the metafor package

Article

作者: Zhao, Peng ; Lu, Yongchao ; Du, Minmin ; Zhao, Ying ; Chen, Xiuying

Abstract:

Background:

Hepatitis B virus (HBV) infection is a worldwide public health burden, especially in Asia and Africa. Concerns were raised that foetal exposure to HBV and antiretroviral therapy (ART) might suppress the innate immune response and reduce the production of hepatitis B surface antibody (HBsAb) in foetuses and infants. We therefore conducted the current study to evaluate the impact of ART on the development of the immune response to HBV in foetuses and infants.

Methods:

We selected lamivudine instead of telbivudine or tenofovir as the intervention measurement because it was the oldest and most widely used ART during pregnancy and its safety data have been sufficiently documented. A comprehensive search was conducted in eight electronic databases, including four Chinese and four English databases. Studies that met the following eligibility criteria were included: human randomized controlled trials (RCTs); participants in the treatment group were exclusively exposed to lamivudine; participants in the control group were exposed to placebo, no treatment or hepatitis B immunoglobulin; all participants were HBV-positive pregnant women with a high viral load and the main outcome of interest was neonatal HBsAb seropositivity. Data were tabulated and analysed using R software.

Results:

Nine RCTs were included and analysed. Compared with controls, lamivudine significantly decreased HBsAb seronegativity in the newborn within 24 h after birth (indicating the foetal immune response to HBV). Similar results were noted in infants within 6–7 months after birth and infants within 12 months (indicating the neonatal immune response to HBV vaccine).

Conclusions:

Lamivudine treatment in late pregnancy boosted the foetal immune response to HBV in utero and enhanced the neonatal immune response to hepatitis B vaccine after birth.

2024-04-01·AIDS (London, England)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy

Article

作者: Fanshawe, Thomas R ; Samsunder, Natasha ; Sookrajh, Yukteshwar ; Hayward, Gail N ; Dorward, Jienchi ; Butler, Christopher C ; Turner, Philip J ; Moodley, Pravikrishnen ; Lessells, Richard ; Garrett, Nigel ; Govender, Katya ; Drain, Paul K

Objective::

We aimed to determine whether urine tenofovir (TFV) and dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations are associated with concurrent HIV viraemia.

Design::

Cross-sectional study among people with HIV (PWH) receiving tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART).

Methods::

We used dual tandem liquid chromatography and mass spectrometry to measure urine TFV and DBS TFV-DP concentrations, and evaluated their associations with concurrent viraemia at least 1000 copies/ml using logistic regression models. In exploratory analyses, we used receiver operating curves (ROCs) to estimate optimal urine TFV and DBS TFV-DP thresholds to predict concurrent viraemia.

Results::

Among 124 participants, 68 (54.8%) were women, median age was 39 years [interquartile range (IQR) 34–45] and 74 (59.7%) were receiving efavirenz versus 50 (40.3%) receiving dolutegravir. Higher concentrations of urine TFV [1000 ng/ml increase, odds ratio (OR) 0.97 95% CI 0.94–0.99, P = 0.005] and DBS TFV-DP (100 fmol/punch increase, OR 0.76, 95% CI 0.67–0.86, P < 0.001) were associated with lower odds of viraemia. There was evidence that these associations were stronger among people receiving dolutegravir than among people receiving efavirenz (urine TFV, P = 0.072; DBS TFV-DP, P = 0.003). Nagelkerke pseudo-R2 for the DBS TFV-DP models was higher for the urine TFV models, demonstrating a stronger relationship between DBS TFV-DP and viraemia. Among people receiving dolutegravir, a DBS TFV-DP concentration of 483 fmol/punch had 88% sensitivity and 85% specificity to predict concurrent viraemia ≥1000 copies/ml.

Conclusion::

Among PWH receiving TDF-based ART, urine TFV concentrations, and in particular DBS TFV-DP concentrations, were strongly associated with concurrent viraemia, especially among people receiving dolutegravir.

178

项与替诺福韦相关的新闻（医药）

2024-07-09

·BioSpace

US Government Files Appeal in High-Stakes HIV PrEP Patent Battle Against Gilead

Pictured: Sign at Gilead's corprate headquarters in Silicon Valley/iStock, Sundry Photography The Biden administration last week appealed a 2023 jury decision , which found that Gilead did not infringe on key government patents in its HIV prevention regimen consisting of the drugs Truvada (emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide). In May 2023, a Delaware jury overwhelmingly took Gilead’s side, noting that the U.S. government did not have enough evidence to establish that using the HIV drugs violated three key patents. The jury also unanimously agreed with the pharma that these patents were invalid in the first place, in part because the technologies they protect were obvious to professionals knowledgeable in the space. In March 2024, a Delaware court gave the government some breathing room when it granted the state’s motion to “upset the jury’s findings” of direct infringement and the invalidity of these patents. In particular, the court ruled against the jury’s verdict that the patents were not infringed but upheld the view that the patents were invalid. The government’s appeal last week—filed by the Department of Justice for the Department of Health and Human Services—seeks to reverse the previous rulings on the invalidity of their patent claims over Truvada and Descovy. First approved in 2004 for the treatment of HIV, Truvada is a combination of two drugs—emtricitabine, a nucleoside reverse transcriptase inhibitor, and a prodrug of tenofovir, which is a nucleotide reverse transcriptase inhibitor. Both of its active ingredients allow Truvada to prevent the HIV virus from infecting a cell and embedding its genetic material into the host’s DNA. In July 2012, the FDA signed off on the preventative use of Truvada, allowing its administration to reduce the risk of sexually acquired HIV. Descovy is a newer generation drug that the FDA approved for HIV prevention in October 2019. It also uses emtricitabine, but combines it with tenofovir alafenamide, another tenofovir prodrug. In November 2019, the Trump administration sued Gilead over the use of Truvada and Descovy, alleging that the combination regimen was first invented by scientists at the Centers for Disease Control and Prevnetion in the early 2000s. “To date, the government has spent hundreds of millions of dollars on clinical studies of these treatment regimens,” the Justice Department wrote in its announcement at the time, adding that Gilead “has repeatedly refused to obtain a license for use of the patented drug regimens, while continuing to profit from hundreds of millions of dollars of publicly funded research.” Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

上市批准专利侵权寡核苷酸临床研究

2024-06-27

·药事纵横

2024CMC-China博览会 BD专场 | 中外路演项目第一弹，3家领先的中国Biotech寻求BD/融资合作

2024年8月16日，“抄底并购元年：中国Biotech的新出路、新活法、新征程”将作为“破局·不内卷——第六届CMC-China博览会”的BD论坛，在苏州博览中心C馆启幕。我们将邀请知名咨询机构代表、MNC BD负责人、中国生物医药领域资深企业家与创业者，通过主题演讲、圆桌对话、项目路演的方式，一同就授权出海、并购、估值、BD策略、Local Pharma策略等话题探讨，希望为中国的Biotech们找到一些新出路。论坛主题 | 抄底并购元年：中国Biotech的新出路、新活法、新征程主办单位 | CMC-China、药融圈协办单位 | 科林利康、博羚资本、美柏医健论坛时间 | 2024年8月16日09:00-17:00 论坛地点 | 苏州博览中心C馆C102会议室本场论坛的上半天，将邀请全球知名咨询公司、MNC、Pharma机构的商务负责人，对“2024全球生物医药License/并购趋势与策略”、“MNC与Biotech的创新合作”、“中国本土Pharma并购Biotech的底层逻辑与风险”等话题进行讨论；下半天，我们将邀请9家中外领先的Biotech公司进行项目路演，寻求BD/融资合作。今天，我们先行揭晓3家参与本场活动的Biotech，它们是：柯君医药聚焦心脑血管和抗病毒的临床阶段创新药公司上海柯君医药科技公司是一家处于临床阶段的创新药初创公司。成立于2018年底，创始人何公欣博士和核心团队来自吉利德和其它MNC，有着及其丰富的药物研发实战经验；参与过多个重磅炸弹级药物研发，包括第一个流感口服药达菲(奥司他韦)，乙肝/HIV核心药TAF，及2024年世界销售额第五的HIV药物Biktarvy。柯君医药拥有自己独特的靶向前药和小核酸核心技术平台，并基于这些技术平台开发出多个管线。目前核心管线是新一代口服+注射抗血小板药物CG-0255，现在正在美国进行注册临床，今年下半年开始中国地区临床，有望2026年实现商业化上市。抗病毒管线也在积极推进中。去年完成亿元规模人民币的B轮融资，目前正在进行B+轮融资。拓弘康恒医药专注于细胞和基因治疗领域的生物研发赋能平台自成立以来，公司在干细胞药物、CAR-T和AAV药物等创新药领域均有产品管线布局，同时，拓弘康恒也拥有国内第一张干细胞和NK细胞制品的“药品生产许可证”，实现了药品级细胞产品的制备与质量控制。人才队伍与项目方面，拓弘康恒践行专业求真的企业精神，科研队伍60%以上具有硕博士学历，已申请知识产权62 项，获得授权34 项，在研细胞创新药6 项，开展临床试验4项，适应症涵盖克罗恩病、复杂性肛瘘、血液肿瘤、实体瘤、年龄相关性黄斑变性和糖尿病性黄斑水肿等重大疾病。本次参会及路演的项目需求是推广拓弘康恒的在研药物人源TH-SC01细胞注射液在克罗恩病肛瘘、复杂性肛瘘和慢性放射性直肠炎等三个适应症有效性数据披露。为真生物 NuRapid-Dx®核酸快检平台是国内首家实现基于CRISPR技术产业化的高精度核酸快检平台助力感染性疾病快速诊断为真生物自2008年创立起，始终秉持临床价值驱动的技术创新，以“新型标志物／底层技术/关键原材料／全自动POCT仪器”的研发及产业化为核心，致力为恶性肿瘤、神经退行性疾病和重大传染性疾病的诊断提供创新解决方案。目前公司已上市7个三类诊断产品，5个二类诊断试剂，2个二类仪器，10+个一类试剂。获批 “江苏省肿瘤分子诊断工程技术研究中心”、苏州工业园区“高原产业”重点企业、苏州市知识产权强企培育工程、博士后工作站、省级企业技术中心等资质和荣誉。 BD合作：NuRapid-Dx®核酸快检平台具有操作简便、快速、准确、成本低廉等优点，尤其适用于现场/自测应用场景。为真生物诚挚地希望能与更多的生物医药企业建立合作关系，将这一创新技术推向更广泛的应用，让更多的患者受益于精准医疗的成果。扫描二维码立即注册我们热忱欢迎中国Pharma、投资机构、CXO等机构代表前来参会，洽谈合作。首批投资机构报名表单 *上下滑动查看

并购细胞疗法引进/卖出

2024-06-24

·药渡

100%预防艾滋！吉利德科学创新药物Lenacapavir 3期临床结果喜人

来源：药渡撰文：睿睿李编辑：哦呼艾滋病是由HIV病毒感染造成的传染性疾病。随着现代抗病毒药物的发展，以及“鸡尾酒疗法”的兴起，HIV感染患者已经能够长期控制病情，并且达到与正常人相当的预期寿命。而且，近年研究发现，在没有受到HIV病毒感染时服用抗病毒药物，可以降低被病毒感染的风险，这种预防HIV感染的方法称为暴露前预防（PrEP）疗法。 2024年6月20日，吉利德科学（Nasdaq：GILD）宣布了一项关键3期临床试验的中期分析结果，表明该公司的同类首创HIV-1衣壳抑制剂Lenacapavir（来那卡帕韦）在女性中达到了100%的HIV预防有效性，并且这个药物仅需一年注射两次，极大地保证了患者的隐私性和依从性。 PART. 01 全球艾滋病防治的进展和挑战联合国艾滋病规划署发布的《2023全球艾滋病防治进展报告 – 终结艾滋病之路》显示，全球目前有3900万艾滋病病毒感染者，其中2980万正在接受抗逆转录病毒治疗。2022年有130万艾滋病病毒新发感染，63万人死于艾滋病相关疾病。图1. 1990年至2022年艾滋病相关死亡人数：现状对比没有抗逆转录病毒疗法的情况（图源：公开数据整理）全球的艾滋病防治工作在以下三个方面实现了有效的进展：消除儿童艾滋病。2022年全球感染艾滋病病毒的妊娠和哺乳期女性中，有82%获得了抗逆转录病毒治疗。2010年至2022年，儿童艾滋病病毒新发感染人数减少了58%，达到了20世纪80年代以来的最低水平。废除有害法律。若干个国家在2022年和2023年废除了有害法律，安提瓜和巴布达、库克群岛、巴巴多斯、圣基茨和尼维斯以及新加坡将同性性关系去罪化。这些举措确保了法律和政策不损害人权，并促进和保护人权，从而促进了艾滋病防治工作的进展。推广抗逆转录病毒治疗。全球接受抗逆转录病毒治疗（ART）的人数增加了4倍，从2010年的770万上升到2022年的2980万。自2000年以来，抗逆转录病毒治疗已挽救了2080万人的生命，同时保护了340万儿童免受艾滋病病毒的威胁。报告也指出了艾滋病防治中存在的挑战：妇女和女童仍然在不成比例地受到影响，特别是在撒哈拉以南的非洲地区。2022年，全球每周有4000名年轻妇女和女童感染艾滋病病毒。在撒哈拉以南非洲的某些艾滋病病毒发病率超过0.3%的地区，仅有42%提供专门针对青春期女性和年轻女性的艾滋病病毒预防项目。亚洲和太平洋地区一些国家的新发感染病例正在以惊人的速度上升。全球近四分之一（23%）的艾滋病病毒新发感染发生在这些地区。东欧和中亚（自2010年以来增加了49%）以及中东和北非（自2010年以来增加了61%）的新发感染人数继续急剧增加。这些趋势主要是由于缺乏针对边缘群体和重点人群的艾滋病病毒预防服务，以及惩罚性法律和社会歧视造成的。艾滋病防治资金支持不足。2022年，国际和各国国内的艾滋病防治资金回落至2013年的水平，约为208亿美元，远低于2025年所需的293亿美元。图2. 按来源分布的中低收入国家艾滋病病毒资金（2010-2022年和2025年目标）（图源：公开数据整理） PART. 02 创新药Lenacapavir的3期临床结果 PURPOSE项目在吉利德具有里程碑式的意义，它是有史以来进行的最全面、最多样化的艾滋病病毒预防试验项目。PURPOSE计划包括世界各地的五项艾滋病病毒预防试验，并且格外关注科学创新、试验设计、社区参与和健康公平。本次公布的试验数据是PURPOSE项目产生的第一批数据，已达到了其关键疗效终点，即每年两次的来那卡帕韦优于每天一次的口服Truvada®（恩曲他滨200mg和富马酸替诺福韦300mg；F/TDF）和背景HIV发病率（bHIV）。基于这些结果，独立数据监测委员会（DMC）建议吉利德停止试验的盲法阶段，并向所有试验参与者提供开放标签Lenacapavir。试验的治疗对象为南非25个地点和乌干达3个地点的5300多名16-25岁的顺性别妇女和少女。研究参与者以2:2:1的比例随机分配，第一组受试者每年接受两次Lenacapavir，第二组每天口服一次Descovy，第三组每天口服一次Truvada。由于已经存在有效的PrEP选择，因此设置安慰剂组不符合道德共识。所以，该试验使用了bHIV作为主要对照，Truvada作为次要对照。在接受Lenacapavir的2134名女性中，没有发生艾滋病病毒感染事件（发病率0.00/100人-年）。接受Truvada的1068名女性中有16例艾滋病病毒感染事件（发病率为1.69/100人-年）。结果表明，每年两次使用Lenacapavir优于bHIV（主要终点，发病率为2.41/100人-年），优于每天一次使用Truvada（次要终点），两个终点均<0.0001。在试验中，Lenacapavir总体耐受性良好，没有发现重大的或新的安全问题。吉利德科学公司首席医疗官、医学博士Merdad Parsey表示：“使用Lenacapavir每年两次可以达到零感染和100%的疗效，证明了其作为预防艾滋病病毒感染重要新工具的潜力。我们期待着正在进行的PURPOSE临床项目取得更多成果，并继续朝着我们的目标努力，即帮助终结艾滋病病毒在世界各地的流行。” 图3. 吉利德的HIV研发管线（图源：药渡数据）此前，2022年8月22日，欧盟委员会（EC）已批准Sunlenca®（lenacapavir）注射剂和片剂的上市申请，用于联合其他抗反转录病毒药物，治疗无法建立抑制病毒机制的多重耐药型HIV成人感染者。 Lenacapavir具有多阶段作用机制，对其他现有药物不存在已知的交叉耐药性，为对现有疗法无有效应答的HIV感染者提供了一种全新的治疗方案。图4. 吉利德Sunlenca®已获FDA批准（图源：公开数据整理）编者按：吉利德Lenacapavir（每年两次）在预防艾滋病病毒方面显示出100%的疗效，显著优于Truvada®（每天一次）。从长效HIV组合到癌症治疗中一些最有前景的靶点，吉利德不断地发现、评估和推进药物研发，为危及生命的疾病开发有效的治疗方法。凭借开创性的科学技术和合作伙伴关系，病毒学、肿瘤学和炎症领域的紧迫临床需求定会得到满足。参考来源： 1. The Path That Ends AIDS: 2023 UNAIDS Global AIDS Update. UNAIDS 2. Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention. GILEAD. June 20, 2024 *声明：本文仅是介绍医药疾病领域研究进展或简述研究概况或分享医药相关讯息，并非也不会进行治疗或诊断方案推荐，也不对相关投资构成任何建议。内容如有疏漏，欢迎沟通指出！点击下方“药渡“，关注更多精彩内容欧洲杯来了！哪些国家最有望夺得“最佳药物管道”奖杯？美国Arthrosi公司创新药AR882溶解痛风石，2期临床试验成果亮相2024欧洲风湿病学大会全球First-in-class！迪哲医药戈利昔替尼重磅获批点击下方关注，聚焦医药创新一手资讯

临床3期

100 项与替诺福韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06074	-	J05AF07	DB14126

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
病毒感染	中国	Pharmacare Srl	2008-06-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乙型肝炎病毒相关肝细胞癌	临床3期	中国台湾	Gilead Sciences, Inc.	2012-09-01
慢性乙型肝炎	临床3期	中国台湾	Gilead Sciences, Inc.	2012-09-01
HIV感染	临床3期	美国	GSK Plc	2003-02-01
怀孕	临床2期	柬埔寨	Gilead Sciences, Inc.	2006-10-01
怀孕	临床2期	科特迪瓦	Gilead Sciences, Inc.	2006-10-01
怀孕	临床2期	南非	Gilead Sciences, Inc.	2006-10-01
病毒血症	临床2期	美国	Gilead Sciences, Inc.	2006-03-01
病毒血症	临床2期	法国	Gilead Sciences, Inc.	2006-03-01
病毒血症	临床2期	德国	Gilead Sciences, Inc.	2006-03-01
病毒血症	临床2期	西班牙	Gilead Sciences, Inc.	2006-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AASLD2023	N/A	肝细胞癌	3,384	Tenofovir disoproxil (TDF)	廠衊蓋壓艱鑰製襯獵鹹(築願選膚餘網壓獵簾齋) = 顧窪壓繭顧艱艱選繭製齋窪襯夢製艱襯鑰壓鬱 (壓鏇糧糧衊遞襯鹹積鑰 ) 更多	-	2023-11-10
				Entecavir (ETV)	廠衊蓋壓艱鑰製襯獵鹹(築願選膚餘網壓獵簾齋) = 鑰艱鏇蓋糧顧製餘鏇築齋窪襯夢製艱襯鑰壓鬱 (壓鏇糧糧衊遞襯鹹積鑰 ) 更多
AASLD2023	N/A	慢性乙型肝炎	330	Tenofovir dis-oproxil fumarate (TDF)	網範憲鹽窪顧壓憲構膚(廠鹽遞膚網觸糧憲廠餘) = 遞築顧簾窪鑰鬱鹽襯鑰鑰繭構醖齋顧鹽選糧糧 (鏇鬱鹹築顧廠構構構獵 ) 更多	-	2023-11-10
AASLD2023	N/A	乙型肝炎 \| 丙型肝炎 \| 代偿期肝硬化	60	SOF/VEL 12-week regimen + prophylactic use of TAF	糧醖鹹鬱壓膚鬱餘獵壓(憲廠夢鹽醖構繭廠夢願) = 構繭選製願鬱鏇廠製鬱襯廠獵願鏇顧淵網鬱選 (鬱醖鏇獵膚簾壓遞網築 )	-	2023-11-10
NCT04686279 (CTgov)	临床1期	获得性免疫缺陷综合征	8	Tenofovir Douche	鬱窪艱顧範遞鑰壓選製(觸鑰餘醖齋夢廠鹹築觸) = 廠蓋廠膚壓觸遞鬱範獵糧壓餘廠糧壓壓夢鹽鏇 (廠鹽觸蓋鏇淵蓋窪鹹窪, 鏇製襯餘廠築艱夢觸衊 ~ 膚餘積齋衊蓋觸鏇鏇壓) 更多	-	2023-10-30
EASL2023	N/A	慢性乙型肝炎一线	852	tenofovir (First-line group)	選衊窪襯鹹醖選構鏇顧(鹽製簾艱壓鬱餘築窪艱) = 網壓顧窪襯鬱繭鬱齋膚遞襯壓鹽鬱鑰醖顧鏇顧 (憲夢簾廠夢鬱衊積蓋範 )	-	2023-06-21
				tenofovir (Rescue group)	選衊窪襯鹹醖選構鏇顧(鹽製簾艱壓鬱餘築窪艱) = 鹹夢願蓋蓋憲襯鏇窪鑰遞襯壓鹽鬱鑰醖顧鏇顧 (憲夢簾廠夢鬱衊積蓋範 )
EASL2023	N/A	乙型肝炎 \| HIV感染	58	tenofovir (Participants with functional HBV cure)	遞夢製鬱簾艱艱廠膚糧(糧觸淵衊範願遞膚糧觸) = 廠網獵衊範鏇糧廠製鹽齋遞壓膚淵鏇齋選鬱餘 (蓋築齋憲繭顧糧顧製獵 ) 更多	-	2023-06-21
				tenofovir (Participants without functional HBV cure)	遞夢製鬱簾艱艱廠膚糧(糧觸淵衊範願遞膚糧觸) = 憲鏇獵觸構壓範積製範齋遞壓膚淵鏇齋選鬱餘 (蓋築齋憲繭顧糧顧製獵 ) 更多
EASL2023	N/A	慢性乙型肝炎	5,366	Tenofovir	窪遞鏇憲齋鑰獵壓鏇膚(構範顧製衊製襯鏇觸構): HR = 0.83 (95% CI, 0.73 ~ 0.95) 更多	-	2023-06-21
				Entecavir
NCT03917420 (CTgov)	临床1期	获得性免疫缺陷综合征	10	Tenofovir 300Mg Oral Tablet+Emtricitabine 200 MG	築獵鬱遞襯鬱廠淵壓範(齋鏇廠構簾鹹鹽齋選糧) = 憲鹽鏇顧製齋齋鬱壓顧齋繭壓醖網鬱窪鬱糧艱 (艱鹽網選糧鑰憲壓鹹鏇, 膚衊衊餘築衊蓋醖壓餘 ~ 鹽鹽艱憲願襯鑰鑰齋淵) 更多	-	2023-04-12
ARTIST (Pubmed)	N/A	二线	62	Tenofovir, lamivudine/emtricitabine, and NNRTI	衊窪製鏇醖齋憲淵鹽壓(壓憲齋願觸膚網繭積衊) = 窪齋齋衊衊廠壓膚繭願製衊鑰窪鹹鑰艱範夢繭 (蓋蓋夢淵鬱願觸廠淵齋, 74 ~ 93)	-	2023-01-25
Pubmed	N/A	慢性乙型肝炎	201	Tenofovir disoproxil fumarate (TDF) + Peginterferon (PegIFN) alfa-2a	願鑰顧齋積網鏇選積憲(齋製衊鬱觸憲選夢遞淵) = 顧醖選範醖糧淵襯積製淵淵觸膚遞襯繭簾淵製 (繭繭網鬱範襯積齋齋淵 )	-	2023-01-05
				Tenofovir disoproxil fumarate (TDF) alone	願鑰顧齋積網鏇選積憲(齋製衊鬱觸憲選夢遞淵) = 網遞繭繭顧範簾獵膚簾淵淵觸膚遞襯繭簾淵製 (繭繭網鬱範襯積齋齋淵 )